

[REDACTED]

[REDACTED]

Dtd. Shillong, the 12<sup>th</sup> Sept., 2023

[REDACTED]

Dt. Shillong, the 01.08.23  
Dt. Shillong, the 17.08.23

Sir/Madam,

Kindly find herewith the analytical report of the following Survey Sample of Drugs. This has a reference to the letter cited above.

The details of the report are also enclosed for necessary.

Registration No.	Name of samples	Manufacturer	Batch No.	Mfg. Date	Exp. Date
[REDACTED]	Maxcefo-100	[REDACTED]	23CT023	07/23	06/25
[REDACTED]	Maxcefo-200	[REDACTED]	23CT025	07/23	06/25
[REDACTED]	Nifedipine-5mg	[REDACTED]	CN160005	07/23	06/25

[REDACTED]

[REDACTED]

Dtd. Shillong, the 12<sup>th</sup> Sept., 2023

Copy to:

1. [REDACTED]
  2. Managing Director, MMDSL, Department of Health & Family Welfare, DHS Complex, Laitumkhrah, Shillong.
- [REDACTED]

Name of the sample and content:

**MAXCEFO-100**


Each uncoated tablet contains:  
Cefpodoxime Proxetil IP  
Eq.to Cefpodoxime.....100mg

Manufacturer's name & address:



Date received: **02.08.2023**

REGISTRATION No.



Batch No. **23CT023**

Mfg. Date **07/23**

Exp. Date **06/25**

Permitted  
Limits

Description: Round tablets, white in colour with convex surfaces and rough edges.

Uniformity of Weights: Conform to specifications prescribed in IP.

Identification Tests: Conform to specifications prescribed in IP.


Dissolution Test: % Dissolution of all tablets taken for the test lies within 70-74%

> 70%

ASSAY: % Content of active component in sample = 99.9 %

90-110%

REMARKS: **SAMPLE PASSED THE TESTS PERFORMED**



Dated: Shillong

The 12/9/23

Name of the sample and content:

**MAXCEFO-200**

Each uncoated tablet contains:  
Cefpodoxime Proxetil IP  
Eq.to Cefpodoxime.....200mg

Manufacturer's name & address:



Date received: **02.08.2023**

REGISTRATION No. 

Batch No. **23CT025**

Mfg. Date **07/23**

Exp. Date **06/25**

Permitted  
Limits

**Description:** Tablets are uncoated, white in colour, rectangular in shape with blunt edges. Surfaces are convex with a breakmark on one side.


**Uniformity of Weights:** Conform to specifications prescribed in IP.

**Identification Tests:** Conform to specifications prescribed in IP.

**Dissolution Test:** % Dissolution of all tablets taken for the test lies within 90-102% > 70%

**ASSAY:** % Content of active component in sample = 106.42 % 90-110%

**REMARKS:** **SAMPLE PASSED THE TESTS PERFORMED**



Dated: Shillong  
The 12/9/23

Name of the sample and content:

**NIFEDIPINE 5mg**

Each hard gelatin capsule contains:

Nifedipine IP.....5mg

Excipients.....q.s.

Approved colour used in empty capsule shell

Manufacturer's name & address:



Date received: **17.08.2023**

REGISTRATION No



Batch No. **CNI60005**

Mfg. Date **07/23**

Exp. Date **06/25**

Permitted  
Limits

**Description:** Capsules consists of two cylindrical shells white and brown in colour overlapping each other. Contents inside is a pale yellow amorphous powder.

**Uniformity of Weights:** Conform to specifications prescribed in IP.


**Identification Tests:** Conform to specifications prescribed in IP.

**Uniformity of Content:** % Concentration of each tablets taken for the test lies within 103-106% 85-115%

**Dissolution Test:** % Dissolution of all tablets taken for the test lies within 74-84% > 70%

**ASSAY:** % Content of active component in sample = 105.3 % 90-110%

REMARKS: **SAMPLE PASSED THE TESTS PERFORMED**



Dated: Shillong

The 12/9/23